| Literature DB >> 25207817 |
Claire da Silva Santos1, Sanaz Attarha2, Ravi Kanth Saini2, Viviane Boaventura3, Jackson Costa4, Ricardo Khouri4, Manoel Barral-Netto5, Cláudia Ida Brodskyn6, Serhiy Souchelnytskyi2.
Abstract
In this study, we used proteomics and biological network analysis to evaluate the potential biological processes and components present in the identified proteins of biopsies from cutaneous leishmaniasis (CL) patients infected by Leishmania braziliensis in comparison with normal skin. We identified 59 proteins differently expressed in samples from infected and normal skin. Biological network analysis employing identified proteins showed the presence of networks that may be involved in the cell death mediated by cytotoxic T lymphocytes. After immunohistochemical analyses, the expression of caspase-9, caspase-3, and granzyme B was validated in the tissue and positively correlated with the lesion size in CL patients. In conclusion, this work identified differentially expressed proteins in the inflammatory site of CL, revealed enhanced expression of caspase-9, and highlighted mechanisms associated with the progression of tissue damage observed in lesions.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25207817 PMCID: PMC4291685 DOI: 10.1038/jid.2014.396
Source DB: PubMed Journal: J Invest Dermatol ISSN: 0022-202X Impact factor: 8.551
Figure 1Images of representative 2D gels. The images are representative of six samples showing separation of proteins extracted from lesions of (a) cutaneous leishmaniasis (CL) patients and (b) normal skin. Directions of isoelectric focusing and SDS-PAGE are indicated on the top and on the side of the left gel image. Spots marked only in gel (a) indicate protein spots unique in the CL samples. Spots marked only in gel (b) show the protein spots unique in normal skin. Spots marked in gels (a, b) indicate protein spots differently regulated between the samples. The protein spots were identified by matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry. List of identified proteins is given in Table 1.
Proteins differently expressed between lesions from CL patients and normal skin
| 1 | TTC37 | Tetratricopeptide repeat domain 37 | 7662078 | 177.5 | 7.7 | 210 | 9.5 | 1.0e+000 | 2.24 | 14 | 13 | Upregulated | |
| 2 | FBF1 | Fas (TNFRSF6) binding factor 1 | 23270771 | 90.58 | 6.7 | 100 | 9.5 | 9.0e-001 | 1.05 | 8 | 11 | Upregulated | |
| 3 | CDK11A | Cyclin-dependent kinase 11A | 66267414 | 53.91 | 4.8 | 51 | 8.2 | 1.0e+000 | 2.24 | 4 | 13 | Unique CL | |
| 4 | AIDA | Chromosome 1 open reading frame 80 | 119626771 | 35.08 | 6.2 | 55 | 7.3 | 1.0e+000 | 2.43 | 6 | 18 | Upregulated | |
| 5 | FAM13C | FAM13C | 119574574 | 55.44 | 6.5 | 50 | 6.8 | 1.0e+000 | 2.43 | 11 | 16 | Unique CL | |
| 6 | CASP9 | Caspase-9 | 158257592 | 47.09 | 5.7 | 40 | 8.3 | 1.0e+000 | 2.43 | 4 | 11 | Upregulated | |
| 7 | RABL2A | RAB, member of RAS oncogene family-like 2A | 220675523 | 18.52 | 4.4 | 25 | 9.2 | 1.0e+000 | 2.34 | 4 | 27 | Unique CL | |
| 8 | TMEM40 | Transmembrane protein 40 | 31542667 | 25.59 | 5.3 | 37 | 8.2 | 1.0e+000 | 2.43 | 4 | 23 | Unique CL | |
| 9 | GAPVD1 | GAPVD1 | 21739944 | 38.70 | 6.3 | 30 | 7.8 | 9.0e-001 | 1.57 | 6 | 15 | Unique CL | |
| 10 | IGBP1 | Immunoglobulin (CD79A) binding protein 1 | 193786113 | 39.28 | 5.2 | 36 | 7.3 | 1.0e+000 | 2.43 | 7 | 22 | Unique CL | |
| 11 | MIF4GD | MIF4G domain-containing protein isoform 1 | 335334986 | 30.70 | 5.2 | 30 | 7.2 | 1.0e+000 | 2.42 | 5 | 21 | Upregulated | |
| 12 | BBOX1 | Gamma-Butyrobetain, 2-Oxoglutarate Dioxygenase 1 | 295982624 | 45.30 | 6.3 | 35 | 5.5 | 1.0e+000 | 2.43 | 6 | 19 | Unique CL | |
| 13 | AKIR1N1 | AKIR1N1 | 119627688 | 18.01 | 7.2 | 15 | 5.8 | 1.0e+000 | 2.25 | 4 | 35 | Unique CL | |
| 14 | CHKA | Choline kinase-α | 118137437 | 45.59 | 6.5 | 41 | 5.4 | 1.0e+000 | 2.41 | 7 | 19 | Unique CL | |
| 15 | METTL10 | METTL10 | 57997124 | 32.13 | 5.8 | 5.0 | 4.3 | 1.0e+000 | 2.05 | 7 | 14 | Unique CL | |
| 16 | TRB | TCR-β | 54292535 | 5.58 | 6.8 | 17 | 4.5 | 1.0e+000 | 2.43 | 4 | 46 | Upregulated | |
| 17 | HAGH | HAGH | 158261333 | 29.19 | 6.5 | 33 | 4.7 | 1.0e+000 | 2.43 | 5 | 27 | Unique CL | |
| 18 | IL12RB1 | Interleukin-12 receptor subunit beta-1 | 24497440 | 43.38 | 6.8 | 40 | 4.5 | 1.0e+000 | 2.43 | 9 | 28 | Unique CL | |
| 19 | SNRNP48 | SNRNP48 | 11957561 | 41.82 | 6.0 | 33 | 4.0 | 1.0e+000 | 1.30 | 6 | 11 | Unique CL | |
| 20 | BRF1 | Transcription factor IIIB 90 kDa | 338753412 | 48.36 | 4.8 | 36 | 3.9 | 1.0e+000 | 2.43 | 7 | 17 | Upregulated | |
| 21 | HAUS5 | HAUS augmin-like complex subunit 5 | 39963101 | 32.91 | 7.2 | 38 | 3.7 | 1.0e+000 | 1.70 | 6 | 25 | Unique CL | |
| 22 | KIR2DL4 | Killer cell receptor | 39963101 | 36.05 | 6.2 | 55 | 5.5 | 1.0e+000 | 2.17 | 3 | 15 | Unique CL | |
| 23 | FKBP4 | FKBP4 | 4503729 | 52.07 | 5.3 | 40 | 3.5 | 1.0e+000 | 2.43 | 8 | 16 | Unique CL | |
| 24 | ATL1 | Atlastin GTPase 1 | 4406632 | 54.50 | 5.8 | 50 | 5.5 | 1.0e+000 | 2.43 | 4 | 13 | Unique CL | |
| 25 | BCAM | Basal cell adhesion molecule | 342196430 | 68.17 | 5.5 | 55 | 3.8 | 1.0e+000 | 2.43 | 7 | 13 | Downregulated | |
| 26 | UBR1 | Ubiquitin protein ligase E3 component n-recognin 1 | 14042752 | 95.40 | 5.8 | 55 | 5.0 | 1.0e+000 | 0.89 | 11 | 15 | Unique CL | |
| 27 | KPNA1 | Karyopherin-α 1 | 222144293 | 60.95 | 4.9 | 53 | 3.6 | 1.0e+000 | 2.43 | 6 | 13 | Unique CL | |
| 28 | DARS | Aspartyl-tRNA synthetase | 45439306 | 57.52 | 6.1 | 52 | 5.5 | 1.0e+000 | 2.43 | 8 | 17 | Unique CL | |
| 29 | cTAGE4 | cTAGE family, member 4 | 193290160 | 88.31 | 5.2 | 66 | 5.6 | 1.0e+000 | 0.87 | 13 | 19 | Upregulated | |
| 30 | TBC1D9B | TBC1D9B | 193786679 | 64.56 | 4.7 | 70 | 3.5 | 1.0e+000 | 1.16 | 7 | 15 | Unique CL | |
| 31 | ATP1A2 | Na(+)/K(+)-ATPase | 193785194 | 73.51 | 5.6 | 65 | 5.8 | 1.0e+000 | 2.43 | 7 | 16 | Upregulated | |
| 32 | RHPN2 | Hypothetical protein Rhophilin-2 | 21732479 | 74.40 | 6.5 | 72 | 5.6 | 1.0e+000 | 2.43 | 5 | 9 | Unique CL | |
| 33 | SKIL | SKI-like isoform 3 | 223029422 | 76.02 | 6.6 | 75 | 5.6 | 1.0e+000 | 2.04 | 7 | 7 | Unique CL | |
| 34 | RNF40 | Ring finger protein 40 | 7662230 | 114.4 | 6.0 | 90 | 4.2 | 1.0e+000 | 2.43 | 10 | 10 | Unique CL | |
| 35 | ANKLE2 | Ankyrin repeat and LEM domain-containing protein 2 | 148664230 | 104.95 | 6.7 | 95 | 3.8 | 1.0e+000 | 1.53 | 7 | 13 | Downregulated | |
| 36 | MYPBC1 | Hypothetical protein MYBPC1 | 30722349 | 88.87 | 5.9 | 150 | 3.5 | 1.0e+000 | 0.91 | 9 | 12 | Unique CL | |
| 37 | PDE4DIP | Phosphodiesterase 4D | 30268245 | 114.62 | 5.0 | 90 | 4.5 | 1.0e+000 | 1.27 | 7 | 8 | Downregulated | |
| 38 | SLC8A1 | SLC8A1 | 163914373 | 105.58 | 4.9 | 95 | 4.7 | 1.0e+000 | 1.88 | 5 | 5 | Downregulated | |
| 39 | SART1 | Squamous cell carcinoma antigen recognized by T cells | 62897593 | 90.42 | 6.0 | 96 | 5.0 | 1.0e+000 | 2.43 | 11 | 15 | Unique CL | |
| 40 | PTPN5 | PTPN5 | 221039972 | 59.64 | 5.0 | 75 | 5.5 | 1.0e+000 | 2.43 | 7 | 8 | Unique CL | |
| 41 | NEK11 | Serine/threonine-protein kinase Nek11 | 41281753 | 54.56 | 5.7 | 51 | 6.3 | 1.0e+000 | 2.43 | 6 | 16 | Unique CL | |
| 42 | ZBTB10 | ZBTB10 | 119607481 | 74.92 | 4.8 | 69 | 8.0 | 1.0e+000 | 20.7 | 5 | 8 | Unique CL | |
| 43 | SNX25 | SNX25 | 193787897 | 83.27 | 5.9 | 70 | 6.8 | 1.0e+000 | 2.43 | 8 | 14 | Unique N. skin | |
| 44 | SPECC1 | SPECC1 | 21706968 | 55.18 | 5.1 | 64 | 8.2 | 1.0e+000 | 2.43 | 12 | 18 | Unique N. Skin | |
| 45 | CENPE | Centromere-associated protein E | 67464447 | 39.55 | 7.0 | 40 | 4.5 | 1.0e+000 | 1.21 | 8 | 29 | Unique N. Skin | |
| 46 | UBOX5 | RING finger protein 37 isoform B | 40806196 | 54.40 | 6.8 | 45 | 4.0 | 1.0e+000 | 2.27 | 5 | 11 | Unique N. Skin | |
| 47 | GNL1 | Guanine nucleotide binding protein-like 1 | 39645120 | 54.32 | 5.0 | 55 | 4.5 | 1.0e+000 | 2.43 | 6 | 10 | Unique N. Skin | |
| 48 | VPS51 | VPS51 | 38014611 | 79.57 | 6.6 | 58 | 4.5 | 1.0e+000 | 2.43 | 10 | 10 | Unique N. Skin | |
| 49 | ALDH2 | Mitochondrial aldehyde dehydrogenase 2 | 48256839 | 56.85 | 6.4 | 63 | 5.3 | 1.0e+000 | 2.43 | 6 | 15 | Unique N. Skin | |
| 50 | SYNE1 | Nesprin-1 | 73909082 | 59.51 | 6.5 | 70 | 5.4 | 1.0e+000 | 2.43 | 8 | 15 | Unique N. Skin | |
| 51 | DCHS2 | Protocadherin protein | 45439306 | 57.52 | 6.1 | 60 | 3.8 | 1.0e+000 | 2.43 | 8 | 13 | Unique N. Skin | |
| 52 | PALD1 | PALADIN | 20521820 | 98.25 | 6.1 | 98 | 5.5 | 1.0e+000 | 2.43 | 9 | 17 | Unique N. Skin | |
| 53 | HNRNPUL2 | Heterogeneous nuclear ribonucleoprotein U-like 2 | 118601081 | 85.66 | 4.9 | 90 | 5.3 | 1.0e+000 | 1.85 | 7 | 18 | Unique N. Skin | |
| 54 | ARHGEF7 | Rho guanine nucleotide exchange factor (GEF) 7 | 55957399 | 71.12 | 6.6 | 72 | 6.3 | 1.0e+000 | 2.43 | 6 | 7 | Unique N. Skin | |
| 55 | CCDC114 | Hypothetical protein FLJ32926 | 119572712 | 80.73 | 5.9 | 85 | 6.8 | 1.0e+000 | 1.53 | 9 | 17 | Unique N. Skin | |
| 56 | IPO7 | Importin-7 | 5453998 | 120.81 | 4.7 | 130 | 7.0 | 1.0e+000 | 1.13 | 10 | 18 | Unique N. Skin | |
| 57 | STK31 | Serine/threonine kinase 31 | 51095006a | 114.25 | 5.0 | 120 | 7.2 | 1.0e+000 | 2.43 | 9 | 13 | Unique N. Skin | |
| 58 | TNS3 | Tensin 3 variant | 62087570 | 137.54 | 6.4 | 121 | 7.4 | 1.0e+000 | 0.92 | 7 | 10 | Unique N. Skin | |
| 59 | ATP2B2 | ATPase, Ca2+ transporting, plasma membrane 3, isoform CRA_b | 119593265 | 128.19 | 5.7 | 119 | 7.6 | 1.0e+000 | 2.31 | 9 | 9 | Unique N. skin | |
Abbreviations: CL, cutaneous leishmaniasis; pI, isoelectric point, MW, molecular weight; N., normal; NCBI, National Center for Biotechnology Information.
Gene Ontology, protein name, NCBI accession number, theoretical value, probability, Z-value, matched peptide, and sequence coverage were obtained by search with Profound.
Experimental values were calculated from migration in 2D gels. The differences observed between the experimental and theoretical MW values (4, 15, 16, 26, and 36) were possibly due to the presence of isoforms or posttranslational modification of proteins.
Figure 2Schematic Venn diagram of the protein spots identified. The Venn diagram shows proteins unique to (a) cutaneous leishmaniasis (CL) patients, (b) normal skin, and (c) overlaps between biologic processes defined by the identified proteins between the samples. The diagram was built upon analysis of the identified proteins using a GoMiner tool. “Biologic Process” category was selected for the analysis of affected functions.
Figure 3Network and canonical pathway built with 59 differentially expressed proteins. (a) Subnetwork modules associated with apoptosis extracted from the whole network using an MCODE tool. (b) Cytotoxic T lymphocyte–mediated apoptosis of target cell network (P<0.003) performed by Ingenuity Pathway analysis. The red color is an indication of the upregulated/unique proteins expressed in cutaneous leishmaniasis (CL) lesions, and green color indicates downregulated/unique proteins expressed in normal skin. Full and dashed lines represent direct and indirect interactions, respectively, between the proteins. Network shapes are represented in the legend.
Figure 4Immunohistochemistry for caspase-9, caspase-3, and granzyme B in samples. Tissue sections of cutaneous leishmaniasis (CL) patients (n=8) were obtained and stained for (a) caspase-9, (c) caspase-3, and (e) granzyme B. Normal skin samples (n=3) were immunostained for (b) caspase-9, (d) caspase-3, and (f) granzyme B. (g) Isotype control is shown. All samples were counterstained with hematoxylin and examined by light microscopy. Scale bar=10 μm.
Figure 5Correlation analysis between the protein expression in tissue from cutaneous leishmaniasis (CL) patients. Correlation analysis between the percentage of expression of (a) caspase-9 and granzyme B, (b) caspase-9 and caspase-3, and (c) caspase-3 and granzyme B in tissues from CL patients (n=8). Statistical comparisons were done using Spearman's (r2) rank test. P<0.05 was considered significant.
Figure 6Correlation analysis between the protein expression and lesion size. Correlation analysis between the percentage of protein expression of (a) caspase-9, (b) caspase-3, and (c) granzyme B and lesion size of cutaneous leishmaniasis (CL) patients (n=8). Statistical comparisons were done using Spearman's (r2) rank test. P<0.05 was considered significant.